Completed PHASE4 INTERVENTIONAL 2-arm NCT00329381

Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy

A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab)on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids

Sponsor: Novartis

Conditions Asthma

Interventions Xolair

Updated 6 times since 2017 Last updated: Jun 3, 2008 Started: May 31, 2006 Primary completion: May 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00329381, this PHASE4 trial focuses on Asthma and remains completed. Sponsored by Novartis, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
University of Mississippi Medical Center

Data source: University of Mississippi Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jackson, United States